The strategy introduces stable components of flu virus to the body to spur universal, and long-lasting DNA-enhanced protection.
Getting a flu shot every year can be a pain. One UW Medicine researcher is hoping to make the yearly poke a thing of the past with the development of a universal vaccine that would protect from all strains of influenza virus, even as the viruses genetically shape-shift from year to year.
The research in Deborah Fuller’s lab uses a DNA vaccine to instruct the individual’s own skin cells to produce antigens and induce antibodies and T cell responses to fight the infection. Her most recent research on this effort was published today in PLOS ONE.
“Relatively speaking, DNA vaccination is the new kid on the block with regard to the types of vaccines,” said Fuller, a professor in the Department of Microbiology at the University of Washington School of Medicine. This year, U.S. medical professionals expect a challenging flu season, with 7,000 confirmedcases reported nationwide by the end of November – double the number from last year at the same time, according to the Centers for Disease Control and Prevention.
The DNA vaccine in Fuller’s lab was engineered by using genetic components of influenza virus – the conserved areas – which do not change. This is one way Fuller’s DNA vaccine gets around the genetic drift, or changes, that occur in influenza strains from year to year, and challenge clinicians who combat the disease.
It is also administered through the epidermis with a “gene gun” device that injects the DNA vaccine directly into the skin cells. The cells then produce the flu vaccine and prompts the body to create antibodies and T-cells to fight infection.
“With the immunized groups, we found that using this conserved component of the virus gave them 100 percent protection against a previous circulating influenza virus that didn’t match the vaccine,” Fuller said. “This was very exciting for us.”
The vaccine developed by Fuller’s lab takes a different approach to attacking the influenza virus within the body. Instead of simply repelling the virus, as on-the-market vaccines do now, this vaccine seeks out infected cells and kills them. The T-cell responses against the virus were so swift and complete in the tested non-human primates that they simply did not get sick, she said. Fuller’s team also was able to direct the T-cells to go to the lungs first, where much of the damage of an influenza infection occurs.
Another advantage: This approach requires production time of about three months, whereas it typically takes about nine months to produce the U.S.-approved vaccine for a flu season that begins in December (in the United States) and runs through February.
Fuller firmly believes this is the new direction of vaccine research.
“We’ve been working essentially with the same vaccine (techniques) over the last 40 years. It’s been a shake-and-bake vaccine: You produce the virus, you kill the virus, you inject it. Now it’s time for vaccines to go through an overhaul, and this includes the influenza vaccine.”
A “universal” vaccine would eliminate the need for yearly flu vaccinations and could be on-hand for rapid deployment should a deadly pandemic strain of the virus emerge.
The idea of a DNA-based vaccine might also pose a mechanism for vaccines for other viruses, such as Zika, and for possible pandemic outbreaks which might emerge in the future, she said.
But don’t expect the vaccine in Fuller’s lab to appear on the drugstore shelves anytime soon. It can take five to 10 years from the time a vaccine shows promising results in the lab to commercial availability.
A deeper look into this research:
In the Fuller lab, senior research scientist, Jim Fuller, engineered a vaccine that contained DNA coding for viral proteins from four different influenza A strains. These proteins, called HA, are targeted by standard vaccines and are known to trigger a strong immune response to each individual strain. In addition, the vaccine included DNA for a protein that is highly conserved and, thus, shared across different strains of virus.
Because DNA vaccines often fail to generate a strong immune response, the researchers sought to boost the vaccine’s effectiveness by fusing the DNA for some of the antigens with DNA proteins from a bacteria, a toxin from E. Coli, and protein from the hepatitis B virus that are known to be antigens that elicit a strong immune response.
In an animal study in cynomolgus macaques, researchers in the Fuller lab, Drs. Merika Treants Koday and Jolie Leonard, found that after three doses, the DNA vaccine generated a strong antibody response against each of the flu strains it targeted. Antibodies bind to and help clear microbial invaders, preventing an infection from taking hold or reducing its severity.
More importantly, the vaccine triggered a strong cellular immune response that was effective not only against the strains covered by the vaccine but also strains that were not.
Deborah Fuller was the co-inventor of the gene gun used in this research, and co-founded Orlance, Inc. a startup which is working on engineering a clinical version of the DNA vaccine delivery system and commercializing it for vaccines, including influenza.
Learn more: Promise seen in one-and-done approach to combat flu
The Latest on: Universal flu protection
[google_news title=”” keyword=”universal flu protection” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Is a flu vaccine with long-term effectiveness on the horizon?on May 14, 2024 at 5:06 pm
A recent study suggests that targeting multiple areas of the flu virus' proteins may be the key to creating a flu vaccine that offers long-term immunity.
- NSW's flu season is on track to arrive early. But who's at risk, and should we be concerned?on May 12, 2024 at 12:47 pm
The flu season for New South Wales has started earlier than expected. But while some experts say this isn't room for huge concern, authorities are calling for the public to receive vaccinations.
- Sanofi and Novavax team up to develop a Covid-flu shoton May 9, 2024 at 4:59 pm
French pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a Covid vaccine and develop another that combines with a flu shot. Under a licensing deal worth ...
- Cows have human flu receptors, study shows, raising stakes on bird flu outbreak in dairy cattleon May 9, 2024 at 4:56 pm
Cows have the same kinds of gateways into their cells as humans and birds, a new study shows. The finding suggests that cows could be mixing bowls - hosts that could help H5N1 bird flu learn to spread ...
- Swine Flu Newson May 7, 2024 at 5:00 pm
Sustained Protection, Biomedical Sciences Researchers Find July 8, 2022 — A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and ...
- No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Keyon May 1, 2024 at 5:00 pm
If you want up-to-date protection, you’re going to be scheduling in that ... and human trials would of course be needed before you could rock up to Walgreens and get your universal flu shot. The ...
- Universal Flu Vaccine May No Longer Be a Long Shoton May 1, 2024 at 5:00 pm
[U.S. Centers for Disease Control] The search for a universal flu vaccine has been long and fraught with ... “Their mechanism of protection is not necessarily to block the first step of infection. So ...
- How The 2024 Bird Flu Outbreak Is Impacting Our Foodon May 1, 2024 at 11:46 am
Prices for farm-level eggs fell by 23.2 percent in March 2024 after increasing by 53.8 percent in February. As you know, the outbreak of Avian Flu that began in 2022 contributed to elevated egg prices ...
- New Strategy Could Lead to Universal, Long-Lasting Flu Shoton May 1, 2024 at 11:23 am
This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a 5-year-old effort to develop a longer-lasting universal flu vaccine that would be able to foil ...
- New strategy could lead to universal, long-lasting flu shoton May 1, 2024 at 11:01 am
This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a 5-year-old effort to develop a longer-lasting universal flu ... of protection have to do ...
via Google News and Bing News